[go: up one dir, main page]

NO911432L - Fremgangsmaate for fremstilling av 3,5-disubstituerte 2-isoksazoliner og isoksazoler. - Google Patents

Fremgangsmaate for fremstilling av 3,5-disubstituerte 2-isoksazoliner og isoksazoler.

Info

Publication number
NO911432L
NO911432L NO91911432A NO911432A NO911432L NO 911432 L NO911432 L NO 911432L NO 91911432 A NO91911432 A NO 91911432A NO 911432 A NO911432 A NO 911432A NO 911432 L NO911432 L NO 911432L
Authority
NO
Norway
Prior art keywords
isoxsazolines
isoxsazoles
disubstituted
procedure
preparation
Prior art date
Application number
NO91911432A
Other languages
English (en)
Other versions
NO911432D0 (no
Inventor
Wilfried Schwab
Hiristo Anagnostopulos
Elena Porsche-Wiebking
John Grome
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO911432D0 publication Critical patent/NO911432D0/no
Publication of NO911432L publication Critical patent/NO911432L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO91911432A 1990-04-12 1991-04-11 Fremgangsmaate for fremstilling av 3,5-disubstituerte 2-isoksazoliner og isoksazoler. NO911432L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4011880 1990-04-12

Publications (2)

Publication Number Publication Date
NO911432D0 NO911432D0 (no) 1991-04-11
NO911432L true NO911432L (no) 1991-10-14

Family

ID=6404301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91911432A NO911432L (no) 1990-04-12 1991-04-11 Fremgangsmaate for fremstilling av 3,5-disubstituerte 2-isoksazoliner og isoksazoler.

Country Status (16)

Country Link
US (1) US5273989A (no)
EP (1) EP0451790A1 (no)
JP (1) JPH04234857A (no)
KR (1) KR910018363A (no)
CN (1) CN1055537A (no)
AU (1) AU7428591A (no)
BR (1) BR9101475A (no)
CA (1) CA2040219A1 (no)
CS (1) CS101391A2 (no)
FI (1) FI911718A (no)
HU (1) HU911183D0 (no)
IE (1) IE911235A1 (no)
IL (1) IL97821A0 (no)
NO (1) NO911432L (no)
PT (1) PT97329A (no)
ZA (1) ZA912701B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020475A1 (en) * 1993-03-02 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Isoxazole derivative
CA2177375A1 (en) * 1993-11-26 1995-06-01 Edward F. Kleinman 3-aryl-2-isoxazolines as antiinflammatory agents
HUT76784A (en) * 1993-11-26 1997-11-28 Pfizer Antiinflammatory isoxazoline compounds and pharmaceutical compositions containing them
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
FR2752163B1 (fr) * 1996-08-12 1998-10-30 Pf Medicament Utilisation de l'efaroxan pour la fabricaton de medicament destine au traitement de la maladie de huntington
KR19990011062A (ko) * 1997-07-21 1999-02-18 손욱 이소옥사졸리딘 고리 함유 액정화합물 및 이를 포함하고 있는 액정 조성물
US6319937B1 (en) * 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
MXPA02002578A (es) 1999-09-08 2002-10-23 Guilford Pharm Inc Compuestos de union a ciclofilina no peptidicos, y su uso.
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
AU2003221322A1 (en) * 2002-03-07 2003-09-16 Sds Biotech K.K. Substituted isoxazole alkylamine derivative and agri- and horticultural fungicide
JP4767850B2 (ja) * 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
ES2286679T3 (es) * 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
CA2587224A1 (en) * 2004-11-19 2006-05-26 Plant Bioscience Limited Microcin b17 analogs and methods for their preparation and use
WO2008150487A2 (en) * 2007-05-31 2008-12-11 Texas Tech University Synthesis of half esters
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
KR20180003534A (ko) * 2015-02-27 2018-01-09 오피 바이오 팩토리 컴퍼니, 리미티드 카케로마이신 및 그의 유도체 제조방법
MY199931A (en) * 2016-11-08 2023-11-29 Bristol Myers Squibb Co 3-substituted propionic acids as alpha v integrin inhibitors
CN111333590B (zh) * 2018-12-18 2022-05-17 沈阳中化农药化工研发有限公司 一种异恶唑烷盐酸盐的制备方法
CN113149926B (zh) * 2021-04-30 2023-05-26 华侨大学 一种3,5-二取代异恶唑衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA826165A (en) * 1969-10-28 Gagneux Andre Process for the production of an isoxazole derivative
US3152139A (en) * 1961-10-17 1964-10-06 Geigy Chem Corp Certain aminoisoxazolone derivatives
CH450423A (de) * 1965-06-03 1968-01-31 Geigy Ag J R Verfahren zur Herstellung von 3-Hydroxy-5-aminomethyl-isoxazol
DK150615C (da) * 1982-10-26 1987-11-09 Cheminova As Fremgangsmaade til fremstilling af substituerede 3-isoxazololer
CA1261335A (en) * 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
US4985428A (en) * 1987-05-20 1991-01-15 Zambon Group S.P.A. Isoxazoles with nootropic activity
DE3736113A1 (de) * 1987-10-26 1989-05-03 Hoechst Ag Arzneimittel, darin enthaltene phosphorhaltige 2-isoxazoline und isoxazole, sowie herstellungsverfahren fuer diese heterocyclischen verbindungen
DE3914969A1 (de) * 1989-05-02 1990-11-08 Schering Ag 5-substituierte 3-arylisoxazol-derivate, deren herstellung und verwendung als schaedlingsbekaempfungsmittel
JP2786683B2 (ja) * 1989-08-15 1998-08-13 三共株式会社 グリコール誘導体およびその用途

Also Published As

Publication number Publication date
CS101391A2 (en) 1991-11-12
US5273989A (en) 1993-12-28
NO911432D0 (no) 1991-04-11
EP0451790A1 (de) 1991-10-16
IE911235A1 (en) 1991-10-23
HU911183D0 (en) 1991-10-28
BR9101475A (pt) 1991-11-26
CN1055537A (zh) 1991-10-23
KR910018363A (ko) 1991-11-30
IL97821A0 (en) 1992-06-21
JPH04234857A (ja) 1992-08-24
CA2040219A1 (en) 1991-10-13
AU7428591A (en) 1991-10-17
PT97329A (pt) 1992-01-31
ZA912701B (en) 1991-12-24
FI911718A0 (fi) 1991-04-10
FI911718A (fi) 1991-10-13

Similar Documents

Publication Publication Date Title
NO911432D0 (no) Fremgangsmaate for fremstilling av 3,5-disubstituerte 2-isoksazoliner og isoksazoler.
NO913234D0 (no) Fremgangsmaate for fremstilling av pyrazolderivater.
NO910766D0 (no) Fremgangsmaate for fremstilling av titandioksyd.
NO912346L (no) Fremgangsmaate for fremstilling av aminobenzodiazepiner.
NO890269D0 (no) Fremgangsmaate for fremstilling av 1,4-disubstituerte-piperidinyl-forbindelser.
NO894539D0 (no) Fremgangsmaate for fremstilling av nye 2'-halomethyliden-,2'-ethenyliden- og 2'-ethynylcytidin-, uriden og guanosinderivater.
NO893826D0 (no) Fremgangsmaate for fremstilling av 2'-halomethyliden, 2'-ethenyliden og 2'-ethenyladenosinderivater.
NO902548L (no) Fremgangsmaate for fremstilling av fenamat-1,3,4-tiadiazoler og 1,3,4 oksadiazoler.
NO900643D0 (no) Fremgangsmaate for fremstilling og anvendelse av 2,3,23-trihydroksi-urs-12-ener og deres derivater.
NO892499L (no) 2,5,6,7-tetranor-4,8-inter-m-fenylen pgi2 derivater, fremgangsmaate for fremstilling av disse, og anvendelse derav.
NO903347D0 (no) Fremgangsmaate for fremstilling av 14,17alfa-ethano- og ethanooestratriener.
NO921086L (no) Fremgangsmaate for fremstilling og anvendelse av substituerte 2',3'-didesoksy-5-trifluormetyluridiner
NO911543L (no) Katalysatorsystem og fremgangsmaate for fremstilling av 1,2-diklorethan.
NO911672L (no) Fremgangsmaate for fremstilling av alkansulfonanilid-derivater.
NO904108D0 (no) Fremstilling av 2,6-dioksypiperidinderivater.
NO891987D0 (no) Fremgangsmaate for fremstilling av n-substituerte fenyltioaniliner, fenylsulfinylaniliner og fenylsulfonylaniliner.
NO901597D0 (no) Tannstikker og fremgangsmaate til fremstilling av samme.
NO901859D0 (no) Festebaand, samt fremgangsmaate for fremstilling av slikt festebaand.
NO913456L (no) Fremgangsmaate for fremstilling av 2',3'-dideoksy-2',3'-didehydronukleosider.
NO913458D0 (no) Fremgangsmaate for fremstilling av 2',3'-dideoksy-2',3'-didehydronukleosider.
NO913457D0 (no) Fremgangsmaate for fremstilling av 2',3'-dideoksy-2',3'-didehydronukleosider.
NO913459D0 (no) Fremgangsmaate for fremstilling av 2',3'-dideoksy-2',3'-didehydronukleosider.
NO883526L (no) Framgangsmaate for framstilling av 1,5-benzotiazepinderivater.
NO883525L (no) Framgangsmaate for framstilling av 1,5-benzotiazepinderivater.
NO913422L (no) Framgangsmaate for framstilling av 1,5-benzotiazepinderivater.